Research work · 2020
Axitinib
National Cancer Institute
Definitions
Abstract
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.
DOI: 10.32388/s1awlw